Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Domestic market and developing countries will need doses of Indian vaccines
Demand normalisation post the second wave contributed to the steady growth
Essential medicines were made available to more than 150 countries around the world during the pandemic
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
